Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis

被引：4

作者：

Khaity, Abdulrhman ^{[1
]}

Mostafa Al-dardery, Nada ^{[2
]}

Albakri, Khaled ^{[3
]}

Abdelwahab, Omar A. ^{[4
]}

Hefnawy, Mahmoud Tarek ^{[5
]}

Yousef, Yaman A. S. ^{[1
]}

Taha, Ruaa E. ^{[6
]}

Swed, Sarya ^{[7
]}

Hafez, Wael ^{[8
,9
]}

Hurlemann, Rene ^{[10
,11
,12
]}

Elsayed, Mohamed E. G. ^{[10
,13
]}

机构：

[1] Elrazi Univ, Fac Med, Khartoum, Sudan

[2] Fayoum Univ, Fac Med, Al Fayyum, Egypt

[3] Hashemite Univ, Fac Med, Zarqa, Jordan

[4] Al Azhar Univ, Fac Med, Cairo, Egypt

[5] Zagazig Univ, Fac Med, Zagazig, Egypt

[6] Khartoum Univ, Fac Med, Khartoum, Sudan

[7] Aleppo Univ, Fac Med, Aleppo, Syria

[8] NMC Royal Hosp, Khalifa City, Abu Dhabi, U Arab Emirates

[9] Natl Res Ctr, Dept Internal Med, Med Res Div, Cairo, Egypt

[10] Carl von Ossietzky Univ Oldenburg, Sch Med & Hlth Sci, Dept Psychiat, Oldenburg, Germany

[11] Univ Hosp Bonn, Dept Psychiat, Bonn, Germany

[12] Carl von Ossietzky Univ Oldenburg, Res Ctr Neurosensory Sci, Oldenburg, Germany

[13] Univ Ulm, Dept Psychiat & Psychotherapy3, Ulm, Germany

来源：

FRONTIERS IN PSYCHIATRY | 2023年 / 14卷

关键词：

schizophrenia; systematic review; meta-analysis; GLP-1 receptor agonists; treatment; CLOZAPINE-ASSOCIATED OBESITY; WEIGHT-LOSS; NONPHARMACOLOGICAL INTERVENTIONS; CARDIOVASCULAR OUTCOMES; GLP-1; LIRAGLUTIDE; EFFICACY; BRAIN; ABNORMALITIES; OVERWEIGHT;

D O I：

10.3389/fpsyt.2023.1153648

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Aims: We performed this meta-analysis to evaluate the efficacy and safety of glucagon-like peptide-1 receptor-agonists (GLP-1RA) treatment on cardio-metabolic parameters among antipsychotic-treated patients with schizophrenia. Methods: We searched the Web of Science, Cochrane Central Register of Controlled Trials, PubMed, PsycINFO, and Scopus for relevant Randomized Clinical trials (RCTs) from inception until 1 August 2022. Documents were screened for qualified articles, and all concerned outcomes were pooled as risk ratios (RR) or mean di erence (MD) in themeta-analysismodels using ReviewManager (RevMan version 5.4). Results: Pooling data from 7 RCTs (398 patients) showed that GLP-1 RA was superior to placebo with regard to body weight [MD = - 4.68, 95% CI (-4.90,-4.46), P < 0.00001], waist circumference [MD = - 3.66, 95% CI (-3.89,-3.44), P < 0.00001], body mass index (BMI) [MD = - 1.09, 95% CI (-1.25,-0.93), P < 0.00001], systolic blood pressure (SBP) [MD = - 3.07, 95% CI (-3.61,-2.53), P < 0.00001], and diastolic blood pressure (DBP) [MD = - 2.02, 95% CI (-2.42,-1.62), P < 0.00001]. The total e ect did not favor either of the two groups with respect to insulin and respiratory adverse events {[MD = - 0.06, 95% CI (-0.36, 0.24), p = 0.70], [RR = 0.66, 95% CI (0.31, 1.40), p = 0.28]; respectively}. Conclusion: Our analysis revealed thatGLP-1 RA treatment is safe and e ective on cardio-metabolic parameters over control in antipsychotic-treated patients with schizophrenia. Nevertheless, the present evidence is not sufficient to confirm the safety and efficacy ofGLP-1RA treatment on insulin and respiratory adverse events. Therefore, further studies are recommended.

引用

页数：15